A Phase II Study of Ribociclib And Endocrine Treatment of Physician s Choice for Locoregional Recurrent Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Brief description of study

Primary Objective: To estimate subsequent recurrence-free survival (RFS) at 3 years for ribociclib when administered with ET (AIs or fulvestrant), in patients with Hormone Receptor (HR) positive, HER2 negative breast cancer with adequately resected local recurrence of early breast cancer (EBC). Secondary Objectives: To estimate distant metastasis-free survival To estimate overall survival (OS). To evaluate safety and tolerability To identify predictors of loco-regional recurrence.


Clinical Study Identifier: s22-00921
ClinicalTrials.gov Identifier: NCT05467891
Principal Investigator: Nancy Chan.
Other Investigators: Yelena Novik, Maryann J Kwa, Theresa Ryan, Jennifer Wu, Marleen I Meyers, Cristian C Papazoglu Statescu, Andrea Popescu-Martinez, Sylvia Adams, Danielle Seidman, Amanda Marie Buzolich, Caitlin Elizabeth Ryan, Anastasiya Apanasyuk, Alexander A Hindenburg, Ruth Oratz, Natalie Jill Klar, Mary Lynn R Nierodzik, Douglas K Marks.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.